Novartis Raises Sales Outlook Through 2031 As Key Medicines Gain Stronger Peak Sales Targets


Date:

(MENAFN- Zex PR Wire) BASEL, Switzerland, November 19, 2026, ZEX PR WIRE, Swiss pharmaceutical company Novartis has updated its medium-term financial outlook, projecting annual net sales growth of approximately 5% at constant currencies between 2026 and 2031.

The company announced the guidance on November 19 as part of its updated strategy presentation for investors and analysts in London. It also expects its core operating income margin to return to above 40% by 2029.

Higher expectations for established medicines

Novartis increased its peak sales expectations for three key medicines.

The company raised the peak sales outlook for Kesimpta from $6 billion to $8 billion. Its target for Scemblix increased from $4 billion to $5 billion, while Leqvio's peak sales guidance also rose from $4 billion to $5 billion.

These changes reflect the company's assessment of the commercial potential of its existing products and the markets they serve.

The updated guidance follows an earlier increase in the company's expectations for Rhapsido, also known as remibrutinib. Novartis now identifies nine marketed medicines with peak sales potential ranging from $3 billion to $10 billion.

Pipeline development remains central to growth

Beyond its existing products, Novartis expects more than 35 potentially submission-enabling clinical readouts through 2031.

The company also highlighted more than 30 potential high-value pipeline assets across its core therapeutic areas and technology platforms. More than 20 are in registration, Phase III or Phase II development, while over 10 are in or entering Phase I.

Ten late-stage assets have multi-billion-dollar peak sales guidance, according to the company.

The pipeline is important because pharmaceutical companies must continually develop new medicines to offset competition, patent expirations and changes in treatment standards.

Margin recovery target

Novartis expects its core operating income margin to return to more than 40% by 2029.

Achieving that target will depend on revenue growth, product mix, research and development spending, manufacturing costs and commercial execution.

The company is positioning its established medicines and development pipeline as the main contributors to its medium-term growth outlook.

What investors will monitor

Investors will follow clinical trial results, regulatory decisions and the commercial performance of the company's medicines over the coming years.

The updated guidance provides a clearer picture of Novartis' expectations through 2031, but the targets remain dependent on clinical outcomes, market adoption and competition in the pharmaceutical industry.

MENAFN19112026004812010992ID1111989114


Zex PR Wire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search